Background And Purpose: In this study we have combined fractionated radiation treatment (RT) with two molecular targeted agents active against key deregulated signaling pathways in head and neck cancer.
Materials And Methods: We used two molecularly characterized, low passage HNSCC cell lines of differing biological characteristics to study the effects of binimetinib and buparlisib in combination with radiation and .
Results: Buparlisib was active against both cell lines whereas binimetinib was more toxic to UT-SCC-14. Neither agent modified radiation sensitivity . Buparlisib significantly inhibited growth of UT-SSC-15 alone or in combination with RT but was ineffective in UT-SCC-14. Binimetinib did cause a significant delay with RT in UT-SCC-14 and it significantly reduced growth of the UT-SCC-15 tumors both alone and with RT. The tri-modality treatment was not as effective as RT with a single effective agent.
Conclusions: No significant benefit was gained by the combined use of the two agents with RT even though each was efficacious when used alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019866 | PMC |
| http://dx.doi.org/10.1016/j.ctro.2018.04.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lead Adsorption and Desorption at the Barite (001) Surface in the Presence of EDTA.
ACS ES T Water
January 2025
School of Earth and Environmental Sciences, Queens College, City University of New York, Queens, New York 11367, United States.
Scaling minerals, such as barite, can cause detrimental consequences for oil/gas pipelines and water systems, but their formation can be inhibited by organic chelators such as ethylenediaminetetraacetic acid (EDTA). Here, we resolve how EDTA affects sorption and desorption of Pb at the barite (001) surface using a combination of X-ray scattering and microscopy measurements. In the presence of EDTA, Pb incorporated in the topmost part of the barite surface and adsorbed as inner-sphere complexes on the surface.
View Article and Find Full Text PDFCancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles.
Theranostics
January 2025
Departments of Radiology, Washington University in St. Louis, MO 63110, USA.
Cancer remains a leading cause of mortality, with aggressive, treatment-resistant tumors posing significant challenges. Current combination therapies and imaging approaches often fail due to disparate pharmacokinetics and difficulties correlating drug delivery with therapeutic response. In this study, we developed radionuclide-activatable theranostic nanoparticles (NPs) comprising folate receptor-targeted bimetallic organo-nanoparticles (Gd-Ti-FA-TA NPs).
View Article and Find Full Text PDFRadiomic signatures of brain metastases on MRI: utility in predicting pathological subtypes of lung cancer.
Transl Cancer Res
December 2024
Department of Radiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Background: The pathological sub-classification of lung cancer is crucial in diagnosis, treatment and prognosis for patients. Quick and timely identification of pathological subtypes from imaging examinations rather than histological tests could help guiding therapeutic strategies. The aim of the study is to construct a non-invasive radiomics-based model for predicting the subtypes of lung cancer on brain metastases (BMs) from multiple magnetic resonance imaging (MRI) sequences.
View Article and Find Full Text PDFIRF5 as a potential immunological biomarker in lung adenocarcinoma.
Transl Cancer Res
December 2024
Department of Oncology, Guangzhou First People's Hospital, Guangzhou, China.
Background: In the clinic, the primary conventional treatments of advanced non-small cell lung cancer (NSCLC) are surgery, radiation therapy, and chemotherapy. In recent years, immune checkpoint inhibitors (ICIs) have shown promise in optimizing therapeutic benefits when combined with other immunotherapies or standard therapies. However, effective biomarkers for distant metastasis or recurrence have yet to be identified, making it difficult to determine the best therapeutic approaches.
View Article and Find Full Text PDFSafety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world study.
Transl Cancer Res
December 2024
GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.
Background: Mecapegfilgrastim, a long-acting granulocyte colony-stimulating factor, is approved in China for neutropenia prevention. However, data on its safety and efficacy in patients with head and neck cancer remain limited. This study aimed to evaluate the safety and efficacy of mecapegfilgrastim in preventing neutropenia among these patients undergoing chemotherapy, particularly those receiving chemoradiotherapy or chemoimmunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!